Piperlongumine (PL) has been showed to have multiple pharmacological activities. In this study, we reported the synthesis of three series of PL derivatives, and evaluation of their anti-inflammatory effects in both lipopolysaccharide (LPS)-induced Raw264.7 macrophages and a dextran sulfate sodium (DSS)-induced mouse model of colitis. Our results presented that two meta-substituent containing derivatives 1-3 and 1-6, in which γ-butyrolactam replaced α,β-unsaturated δ-valerolactam ring of PL, displayed low cytotoxicity and effective anti-inflammatory activity. Molecular docking also showed that the meta-substituted derivative, compared with the corresponding ortho- or para-substituted derivative, had significant interactions with the amino acid residues of CD14, which was the core receptors recognizing LPS. In vitro and in vivo studies, 1-3 and 1-6 could inhibit the expression of pro-inflammatory cytokines, and the excessive production of reactive nitrogen species and reactive oxygen species. Oral administration of 100 mg/kg/day of 1-3 or 1-6 alleviated the severity of clinical symptoms of colitis in mice, and significantly reduced the colonic tissue damage to protect the colonic tissue from the DSS-induced colitis. These results suggested that meta-substituted derivatives 1-3 and 1-6 were potential anti-inflammatory agents, which may lead to future pharmaceutical development.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bioorg.2021.105465 | DOI Listing |
Occup Environ Med
March 2025
Division of Occupational, Environmental and Climate Medicine, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Objectives: We aimed to estimate the prevalence of chronic bronchitis (CB), examine its association with occupational exposure to irritants assessed by self-reporting or the Nordic job exposure matrix (N-JEM) stratified by smoking status and estimate the population-attributable fraction (PAF) of CB from occupational exposure.
Methods: A two-phased, cross-sectional design was used to analyse a random sample collected in 2013 and 2018 of the population aged 16-55 years in Telemark County, Norway. CB was defined as cough and sputum production for ≥3 months over 2 consecutive years.
BMJ Open
March 2025
Department of Adult Health Nursing, Debre Tabor University, Debre Tabor, Ethiopia.
Objective: This study aimed to investigate patients' perceptions of nurse caring behaviours and their determinant factors at Debre Tabor Comprehensive Specialised Hospital (DTCSH) in Debre Tabor city, Ethiopia.
Design: A facility-based cross-sectional study was conducted among 474 patients admitted to the inpatient ward.
Setting: The study was conducted at DTCSH in Debre Tabor city.
JAMA Netw Open
March 2025
Exercise Medicine Research Institute, Edith Cowan University, Perth, Australia.
Importance: Sexual dysfunction is a common adverse effect of prostate cancer treatment, and current management strategies do not adequately address physical and psychological causes. Exercise is a potential therapy in the management of sexual dysfunction.
Objective: To investigate the effects of supervised, clinic-based, resistance and aerobic exercise with and without a brief psychosexual education and self-management intervention (PESM) on sexual function in men with prostate cancer compared with usual care.
BMC Public Health
March 2025
Center for Community Health Studies, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur, 50300, Malaysia.
Background: High-intensity interval training and breathing exercises alone have well-documented health benefits in people with hypertension. This study aimed to investigated the effects of combining the two methods on physical health among adults with hypertension.
Methods: Ninety-six adults (59.
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, was effective and well tolerated at a dose of 6 mg once daily through 1 year (52 weeks) in patients with moderate to severe plaque psoriasis in the phase 3 POETYK PSO-1 and POETYK PSO-4 trials. Patients completing PSO-1 or PSO-4 could enter the ongoing POETYK long-term extension trial and receive open-label deucravacitinib. Safety and efficacy were evaluated through 3 years (148 weeks; data cutoff date: June 15, 2022) in Japanese patients in these trials.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!